Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Immune Dynamics Associated with Patient Outcomes Identified By Multimodal Single-Cell Analysis in Multiple Myeloma Patients Receiving Talquetamab Monotherapy

Blood (2023) 142 (Supplement 1): 1927.

https://doi.org/10.1182/blood-2023-185308

Published: 2023

Journal Articles

Inflammatory Biomarkers and Outcomes in Multiple Myeloma Patients after CAR T-Cell Therapy

Darren Denjay Pan, Tarek H. Mouhieddine, Weijia Fu, Erin Moshier, Samir Parekh, Sundar Jagannath, Adriana C Rossi, Hearn Jay Cho, Joshua Richter, Larysa J Sanchez, Santiago Thibaud, Cesar Rodriguez, Shambavi Richard

Blood (2023) 142 (Supplement 1): 92.

https://doi.org/10.1182/blood-2023-188310

Published: 2023

Journal Articles

Confirmed Pathogenic Germline Variants in Cancer Predisposition Genes Incidentally Detected in Somatic Genomic Profiling of Multiple Myeloma Patients

Santiago Thibaud, William Genthe, Saoirse Bodnar, Alessandro Lagana, Jane Houldsworth, Ajai Chari, Adriana C Rossi, Cesar Rodriguez, Larysa J Sanchez, Shambavi Richard, Joshua Richter, Kenan Onel, Sundar Jagannath, Tehilla Brander, Samir Parekh

Blood (2023) 142 (Supplement 1): 534.

https://doi.org/10.1182/blood-2023-190878

Published: 2023

Journal Articles

Timing of Vaccination Impacts Serological Response to COVID-19 Myeloma Patients after BCMA-Targeted CAR T

Blood (2023) 142 (Supplement 1): 3350.

https://doi.org/10.1182/blood-2023-184409

Published: 2023

Journal Articles

Durable MRD and Imaging-Negative Remission ≥ 5 Years Post-Therapy Predicts Long-Term Progression-Free Survival in Multiple Myeloma Patients - a Single-Center Observational Study

Lucia Y Chen, Santiago Thibaud, Ajai Chari, Joshua Richter, Hearn Jay Cho, Larysa J Sanchez, Cesar Rodriguez, Adriana C Rossi, Shambavi Richard, Samir Parekh, Sundar Jagannath

Blood (2023) 142 (Supplement 1): 1998.

https://doi.org/10.1182/blood-2023-190368

Published: 2023

Journal Articles

Multimodal Single-Cell Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 93.

https://doi.org/10.1182/blood-2023-186395

Published: 2023

Journal Articles

Early and Consistent CRS Detection Using Wearable Device for Remote Patient Monitoring Following CAR-T Therapy in Relapsed/Refractory Multiple Myeloma (RRMM): Early Results of an Investigator-Initiated Trial

Blood (2023) 142 (Supplement 1): 1007.

https://doi.org/10.1182/blood-2023-181936

Published: 2023

Journal Articles

Outcomes after CAR T Cells in Multiple Myeloma Patients with Extramedullary and Paramedullary Disease

Darren Pan, Tarek H. Mouhieddine, Weijia Fu, Erin Moshier, Samir Parekh, Sundar Jagannath, Adriana C Rossi, Joshua Richter, Cesar Rodriguez, Larysa J Sanchez, Santiago Thibaud, Hearn Jay Cho, Shambavi Richard

Blood (2023) 142 (Supplement 1): 1006.

https://doi.org/10.1182/blood-2023-177749

Published: 2023

Journal Articles

Inflammatory Marker Levels, Age, Race and Prior Treatment Burden Independently Predict Delayed Hematologic Recovery after BCMA-Directed CART Therapy in Multiple Myeloma

Santiago Thibaud, Jerrel Catlett, Saoirse Bodnar, MD Babu Mia, Ajai Chari, Joshua Richter, Hearn Jay Cho, Larysa J Sanchez, Cesar Rodriguez, Adriana C Rossi, Sundar Jagannath, Shambavi Richard, Samir Parekh

Blood (2023) 142 (Supplement 1): 2002.

https://doi.org/10.1182/blood-2023-190772

Published: 2023

Journal Articles

Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

Blood (2023) 141 (7): 756–765.

https://doi.org/10.1182/blood.2022017848

Published: 2023

Includes: Supplemental data

Journal Articles

Gain of chr1q Portends Poor Outcomes in Multiple Myeloma Patients Treated with Venetoclax

Alessandro Lagana, Santiago Thibaud, David T. Melnekoff, Paula Restrepo, Violetta Leshchenko, Jonathan McCafferty, Scott Newman, Abbi Kern, David Corrigan, Feras Hantash, Adriana Rossi, Cesar Rodriguez, Larysa Sanchez, Shambavi Richard, Ajai Chari, Hearn J. Cho, Sundar Jagannath, Joshua Richter, Samir Parekh

Blood (2022) 140 (Supplement 1): 4388–4390.

https://doi.org/10.1182/blood-2022-166572

Published: 2022

Journal Articles

Immune Recovery Post BCMA CAR-T: Implications for Infection Prophylaxis and Vaccinations

Shambavi Richard, Guido Lancman, Santiago Thibaud, Ajai Chari, Samir Parekh, Adriana Rossi, Hearn J. Cho, Larysa Sanchez, Joshua Richter, Cesar Rodriguez, Elizabeth Aronson, Karen Louw, Kiah Purcell, Daniel Verina, Juliet Escalon, Sundar Jagannath

Blood (2022) 140 (Supplement 1): 7444–7446.

https://doi.org/10.1182/blood-2022-170404

Published: 2022

Journal Articles

Timing and Nature of Infections in Multiple Myeloma Patients Treated with Anti-BCMA CAR-T Cells

Guido Lancman, Margaret Shyu, Megan Metzger, Kian Parsa, Hearn J. Cho, Samir Parekh, Joshua Richter, Cesar Rodriguez, Adriana Rossi, Larysa Sanchez, Santiago Thibaud, Sundar Jagannath, Ajai Chari, Shambavi Richard

Blood (2022) 140 (Supplement 1): 7198–7199.

https://doi.org/10.1182/blood-2022-163757

Published: 2022

Journal Articles

Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

Guido Lancman, Kian Parsa, Cesar Rodriguez, Joshua Richter, Hearn J. Cho, Samir Parekh, Shambavi Richard, Adriana Rossi, Larysa Sanchez, Santiago Thibaud, Sundar Jagannath, Ajai Chari

Blood (2022) 140 (Supplement 1): 10073–10074.

https://doi.org/10.1182/blood-2022-163733

Published: 2022

Journal Articles

Extramedullary Relapse Post CAR-T

Shambavi Richard, Guido Lancman, Adriana Rossi, Ajai Chari, Samir Parekh, Larysa Sanchez, Cesar Rodriguez, Hearn J. Cho, Joshua Richter, Santiago Thibaud, Kiah Purcell, Elizabeth Aronson, Daniel Verina, Juliet Escalon, Karen Louw, Sundar Jagannath

Blood (2022) 140 (Supplement 1): 4301–4302.

https://doi.org/10.1182/blood-2022-170119

Published: 2022

Journal Articles

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

Blood (2022) 140 (Supplement 1): 614–616.

https://doi.org/10.1182/blood-2022-165646

Published: 2022

Journal Articles

Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics

Blood (2021) 138 (Supplement 1): 2583.

https://doi.org/10.1182/blood-2021-150561

Published: 2021

Journal Articles

Clinical Outcomes of Relapsed/Refractory Multiple Myeloma Patients Following Treatment with Bispecific Antibodies (BiAbs)

Tarek H. Mouhieddine, Oliver Van Oekelen, Darren Pan, Sarita Agte, Adolfo Aleman, David T. Melnekoff, Guido Lancman, Santiago Thibaud, Larysa Sanchez, Shambavi Richard, Joshua Richter, Hearn Jay Cho, Ajai Chari, Sundar Jagannath, Samir Parekh

Blood (2021) 138 (Supplement 1): 821.

https://doi.org/10.1182/blood-2021-151585

Published: 2021

Journal Articles

Pathogenic Germline Variants in Multiple Myeloma

Santiago Thibaud, Aaron Etra, Ryan Subaran, Zachry Soens, Scott Newman, Rong Chen, Ajai Chari, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, David T. Melnekoff, Shambavi Richard, Joshua Richter, Larysa Sanchez, Kuan-lin Huang, Alessandro Lagana, Samir Parekh, Kenan Onel

Blood (2021) 138 (Supplement 1): 399.

https://doi.org/10.1182/blood-2021-151495

Published: 2021

Journal Articles

Outcomes of COVID-19 Infection in Patients Receiving Ruxolitinib and Hypomethylating Agent Therapy

Daniel I. Nathan, MD, Douglas Tremblay, MD, Santiago Thibaud, MD, John Mascarenhas, MD, Janice L. Gabrilove, MD

Blood (2020) 136 (Supplement 1): 30.

https://doi.org/10.1182/blood-2020-137005

Published: 2020

NARROW

Immune Dynamics Associated with Patient Outcomes Identified By Multimodal Single-Cell Analysis in Multiple Myeloma Patients Receiving Talquetamab Monotherapy

Inflammatory Biomarkers and Outcomes in Multiple Myeloma Patients after CAR T-Cell Therapy

Confirmed Pathogenic Germline Variants in Cancer Predisposition Genes Incidentally Detected in Somatic Genomic Profiling of Multiple Myeloma Patients

Timing of Vaccination Impacts Serological Response to COVID-19 Myeloma Patients after BCMA-Targeted CAR T

Durable MRD and Imaging-Negative Remission ≥ 5 Years Post-Therapy Predicts Long-Term Progression-Free Survival in Multiple Myeloma Patients - a Single-Center Observational Study

Multimodal Single-Cell Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Multiple Myeloma

Early and Consistent CRS Detection Using Wearable Device for Remote Patient Monitoring Following CAR-T Therapy in Relapsed/Refractory Multiple Myeloma (RRMM): Early Results of an Investigator-Initiated Trial

Outcomes after CAR T Cells in Multiple Myeloma Patients with Extramedullary and Paramedullary Disease

Inflammatory Marker Levels, Age, Race and Prior Treatment Burden Independently Predict Delayed Hematologic Recovery after BCMA-Directed CART Therapy in Multiple Myeloma

Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

Gain of chr1q Portends Poor Outcomes in Multiple Myeloma Patients Treated with Venetoclax

Immune Recovery Post BCMA CAR-T: Implications for Infection Prophylaxis and Vaccinations

Timing and Nature of Infections in Multiple Myeloma Patients Treated with Anti-BCMA CAR-T Cells

Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

Extramedullary Relapse Post CAR-T

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics

Clinical Outcomes of Relapsed/Refractory Multiple Myeloma Patients Following Treatment with Bispecific Antibodies (BiAbs)

Pathogenic Germline Variants in Multiple Myeloma

Outcomes of COVID-19 Infection in Patients Receiving Ruxolitinib and Hypomethylating Agent Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only